Has Hoonmo Koo, MD received payments from drug or device companies?

Yes. Drug and device makers reported $5,926 in general payments to Hoonmo Koo, MD across 29 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Hoonmo Koo, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Hoonmo Koo, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Hoonmo Koo, MD

Infectious Disease · Houston, TXNPI 1386803336

Payments from drug & device makers

$5,926in general payments, 2019–2025

Across 29 payments — averaging $204.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Melinta Therapeutics, LLC$5K
Geistlich Pharma, North America, Inc.$310
Shockwave Medical, Inc$307
Shionogi Inc$91

What the payments were for

Speaking & faculty fees$4,55077%
Travel & lodging$4217%
Food & beverage$94316%
Education$120%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Melinta Therapeutics, LLC	8	$5,218
Geistlich Pharma, North America, Inc.	1	$310
Shockwave Medical, Inc	18	$307
Shionogi Inc	2	$91

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Vabomere$5,180
BIOMATERIALS$310

How this compares

$5,926 in reported general payments places this provider in the 75th percentile of 576 infectious disease providers in Texas.

See all infectious disease providers in Texas →

Medicare billing

Part B allowed, 2024

$152,010

Medicare patients

306

Services billed

1,412

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Daptomycin	44	$89,931
ZerbaxaCeftolozane/Tazobactam	12	$36,422
Cefepime Hcl	57	$11,722
CeftriaxoneCeftriaxone Sodium	19	$7,046
Vancomycin Hcl	48	$6,671
ErtapenemErtapenem Sodium	13	$5,588
Minocycline Hcl	25	$1,782
Meropenem	13	$1,367
Sodium Chloride0.9 % Sodium Chloride	16	$1,307
Amoxicillin	40	$448

Paid to pharmacies, not to this prescriber.

Other infectious disease in Houston

Eleftherios MylonakisHouston$6.4M
Roberto ArduinoHouston$2.1M
Issam RaadHouston$2M
Joseph GatheHouston$1.9M
Kevin GrimesHouston$1.9M
Jennifer WhitakerHouston$1.5M
Karen VigilHouston$1.4M
Roy ChemalyHouston$1.2M
David HuangHouston$884K
Luis OstroskyHouston$731K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →